Cargando…
Association of patient activity bio-profiles with health-related quality of life in patients with newly diagnosed multiple myeloma: a prospective observational cohort study
BACKGROUND: Due to the nature of their disease, patients with multiple myeloma (MM) often have bone disease-related pain that limits physical activity and diminishes health-related quality of life (HRQOL). Digital health technology with wearables and electronic patient reported outcome (ePRO) tools...
Autores principales: | Korde, Neha, Tavitian, Elizabet, Mastey, Donna, Lengfellner, Joseph, Hevroni, Gil, Zarski, Andrew, Salcedo, Meghan, Mailankody, Sham, Hassoun, Hani, Smith, Eric L., Hultcrantz, Malin, Shah, Urvi, Tan, Carlyn, Diamond, Benjamin, Shah, Gunjan, Scordo, Michael, Lahoud, Oscar, Chung, David J., Landau, Heather, Giralt, Sergio, Derkach, Andriy, Atkinson, Thomas M., Sabbatini, Paul, König, Francesca, Usmani, Saad Z., Landgren, Ola, Lesokhin, Alexander M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989635/ https://www.ncbi.nlm.nih.gov/pubmed/36895800 http://dx.doi.org/10.1016/j.eclinm.2023.101854 |
Ejemplares similares
-
Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023) -
Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice‐weekly carfilzomib (45 and 56 mg/m(2)) in combination with lenalidomide and dexamethasone
por: Korde, Neha, et al.
Publicado: (2021) -
P962: COMMERCIAL TECLISTAMAB IN ANTI-BCMA THERAPY EXPOSED RELAPSED REFRACTORY MULTIPLE MYELOMA PATIENTS: THE MSKCC EXPERIENCE.
por: Firestone, Ross, et al.
Publicado: (2023) -
Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023) -
P886: AFRICAN AMERICAN PATIENTS WITH SMOLDERING MULTIPLE MYELOMA MAY HAVE A LOWER RISK OF PROGRESSION COMPARED TO WHITE PATIENTS
por: Akhlaghi, T., et al.
Publicado: (2022)